Lori Quinn1, Katy Hamana2, Mark Kelson3, Helen Dawes4, Johnny Collett4, Julia Townson3, Raymund Roos5, Anton Adriaan van der Plas5, Ralf Reilmann6, Jan C Frich7, Hugh Rickards8, Anne Rosser9, Monica Busse10. 1. School of Healthcare Sciences, Cardiff University, UK; Department of Biobehavioral Sciences, Teachers College, Columbia University, USA. Electronic address: lq2165@tc.columbia.edu. 2. School of Healthcare Sciences, Cardiff University, UK. 3. South East Wales Trials Unit, Centre for Trials Research, Cardiff University, UK. 4. Oxford Institute of Nursing and Allied Health Research Oxford Brookes University, UK. 5. Department of Neurology, Leiden University Medical Centre, Leiden, Netherlands. 6. George-Huntington-Institute, Münster, Germany; Dept. of Radiology, University of Münster, Münster, Germany; Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Germany. 7. Vikersund Rehabilitation Centre, Vikersund, Norway; Faculty of Medicine, University of Oslo, Norway. 8. Institute of Clinical Sciences, University of Birmingham, UK. 9. Cardiff Brain Repair Group, Neuroscience and Mental Health Institute, MRC Centre for Neuropsychiatric Genetics and Genomics, Schools of Medicine and Biosciences, Cardiff University, Cardiff, CF10 3BB, UK. 10. School of Healthcare Sciences, Cardiff University, UK; South East Wales Trials Unit, Centre for Trials Research, Cardiff University, UK.
Abstract
INTRODUCTION: This study aimed to evaluate the feasibility and benefit of a structured exercise intervention in people with Huntington's Disease (HD). METHODS: This study was conducted at 6 sites, and participants were randomized into either exercise or control (usual care) groups, and were assessed at baseline, 13 and 26 weeks. The intervention was a 12 week, three times per week progressive exercise program, including aerobic (stationary cycling) and upper and lower body strengthening exercise with tapered 1:1 support for 20 of 36 sessions. RESULTS:314 adults were assessed for eligibility: 248 did not meet inclusion criteria, 34 declined, and 32 were recruited and randomized. Three individuals in the intervention group were withdrawn within the first month due to concomitant medical conditions, resulting in 14 participants in intervention and 15 in control groups. There were two AEs in the intervention group, both related to previous medical conditions, and there were two SAEs, both in the control group. The intervention group had better fitness (predicted VO2 max difference: 492.3 ml min-1, 95% CI: [97.1, 887.6]), lower UHDRS mMS (difference 2.9 points, 95% [-5.42, -0.32]) and lower weight at Week 13 (difference 2.25 kg, 95% CI: [-4.47, -0.03]). CONCLUSION: This study demonstrates that a short-term exercise intervention is safe and feasible. Individuals with HD may benefit from structured exercise, and intensity, monitoring and support may be key factors in optimizing response. Larger scale trials are now required to fully elucidate the extended clinical potential of exercise in HD. TRIAL REGISTRATION: Current Controlled Trials ISRCTN11392629.
RCT Entities:
INTRODUCTION: This study aimed to evaluate the feasibility and benefit of a structured exercise intervention in people with Huntington's Disease (HD). METHODS: This study was conducted at 6 sites, and participants were randomized into either exercise or control (usual care) groups, and were assessed at baseline, 13 and 26 weeks. The intervention was a 12 week, three times per week progressive exercise program, including aerobic (stationary cycling) and upper and lower body strengthening exercise with tapered 1:1 support for 20 of 36 sessions. RESULTS: 314 adults were assessed for eligibility: 248 did not meet inclusion criteria, 34 declined, and 32 were recruited and randomized. Three individuals in the intervention group were withdrawn within the first month due to concomitant medical conditions, resulting in 14 participants in intervention and 15 in control groups. There were two AEs in the intervention group, both related to previous medical conditions, and there were two SAEs, both in the control group. The intervention group had better fitness (predicted VO2 max difference: 492.3 ml min-1, 95% CI: [97.1, 887.6]), lower UHDRS mMS (difference 2.9 points, 95% [-5.42, -0.32]) and lower weight at Week 13 (difference 2.25 kg, 95% CI: [-4.47, -0.03]). CONCLUSION: This study demonstrates that a short-term exercise intervention is safe and feasible. Individuals with HD may benefit from structured exercise, and intensity, monitoring and support may be key factors in optimizing response. Larger scale trials are now required to fully elucidate the extended clinical potential of exercise in HD. TRIAL REGISTRATION: Current Controlled Trials ISRCTN11392629.
Authors: Noelle E Carlozzi; Nicholas R Boileau; Kelvin L Chou; Rebecca E Ready; David Cella; Michael K McCormack; Jennifer A Miner; Praveen Dayalu Journal: Mov Disord Date: 2019-11-14 Impact factor: 10.338
Authors: Noelle E Carlozzi; Rebecca E Ready; Samuel Frank; David Cella; Elizabeth A Hahn; Siera M Goodnight; Stephen G Schilling; Nicholas R Boileau; Praveen Dayalu Journal: Mov Disord Date: 2017-05-27 Impact factor: 10.338
Authors: J J Steventon; J Collett; H Furby; K Hamana; C Foster; P O'Callaghan; A Dennis; R Armstrong; A H Németh; A E Rosser; K Murphy; L Quinn; M Busse; H Dawes Journal: Parkinsonism Relat Disord Date: 2018-04-14 Impact factor: 4.402
Authors: Monica Busse; Lori Quinn; Cheney Drew; Mark Kelson; Rob Trubey; Kirsten McEwan; Carys Jones; Julia Townson; Helen Dawes; Rhiannon Tudor-Edwards; Anne Rosser; Kerenza Hood Journal: Phys Ther Date: 2017-06-01